Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Paul Ausick | Mar 5, 2013 at 7:55 AM EST

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

ThinkstockThe U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s…

Jon C. Ogg | Mar 1, 2013 at 3:06 PM EST

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

ThinkstockThe hunt by Big Pharma stocks for smaller drug companies and biotech stocks continues. A report citing “sources” from Dow…

Jon C. Ogg | Mar 1, 2013 at 11:10 AM EST

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are…

Jon C. Ogg | Feb 28, 2013 at 12:50 PM EST

ETF Folly: Biotech ETFs, Nothing but Confusion

Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or…

Jon C. Ogg | Feb 25, 2013 at 5:08 PM EST

VIVUS Obesity Drug Sales Only About 60% of Expectations

ThinkstockVIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings…

Jon C. Ogg | Feb 25, 2013 at 11:25 AM EST

FDA Response Letter Takes over $100M from Dynavax Value

ThinkstockDynavax Technologies Corp. (NASDAQ: DVAX) was a small cap stock even before today’s news, but a complete response letter from…

Jon C. Ogg | Feb 25, 2013 at 8:15 AM EST

Deadly Dialysis Injection Recall Implodes Affymax

ThinkstockAnother big implosion is taking place in the world of biotech and biohealth. Affymax Inc. (NASDAQ: AFFY) and Takeda Pharmaceutical…

Jon C. Ogg | Feb 22, 2013 at 9:55 AM EST

Celsion Raises Much Needed Capital

ThinkstockCelsion Corp. (NASDAQ: CLSN) was one of the more recent biotech implosions we have monitored. The company’s situation looked dire, and…

Jon C. Ogg | Feb 22, 2013 at 9:15 AM EST

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

ThinkstockIt is not unusual to see biotech and biohealth companies raise cash after good news. After all, these companies either need…

Jon C. Ogg | Feb 21, 2013 at 5:20 PM EST

Europe Denies Obesity Drug Approval

ThinkstockIf you are obese in Europe, you are not about to get a little pill to take to help you change.…

Jon C. Ogg | Feb 21, 2013 at 8:15 AM EST

Repros Blasts Off After FDA Study Clearance

ThinkstockRepros Therapeutics Inc. (NASDAQ: RPRX) is surging on clinical update news this Thursday. The company’s Androxal Phase 3 program has…

Jon C. Ogg | Feb 20, 2013 at 4:27 PM EST

Ambit Biosciences Files for IPO

ThinkstockAmbit Biosciences Corp. has filed its paperwork with the Securities and Exchange Commission to come public via an initial public…

Jon C. Ogg | Feb 20, 2013 at 4:04 PM EST

Chelsea Therapeutics Back on the Map in a Serious Way

ThinkstockWhen Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) announced that the U.S. Food & Drug Administration was going to allow the…

Jon C. Ogg | Feb 20, 2013 at 9:10 AM EST

Celgene: When Biotechs Use Stock Buybacks to Juice Price and Earnings

ThinkstockWhen companies start buying back their common stock on the open market, it can have multiple outcomes. It can offset…

Jon C. Ogg | Feb 19, 2013 at 9:00 AM EST

Proposed 2014 Medicare Rates Slam Humana and Other Insurers

ThinkstockHumana Inc. (NYSE: HUM) is leading the large health insurance providers lower as the week gets off to a start.…

1 … 306 307 308 309 310 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

ETF Folly: Biotech ETFs, Nothing but Confusion

VIVUS Obesity Drug Sales Only About 60% of Expectations

FDA Response Letter Takes over $100M from Dynavax Value

Deadly Dialysis Injection Recall Implodes Affymax

Celsion Raises Much Needed Capital

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

Europe Denies Obesity Drug Approval

Repros Blasts Off After FDA Study Clearance

Ambit Biosciences Files for IPO

Chelsea Therapeutics Back on the Map in a Serious Way

Celgene: When Biotechs Use Stock Buybacks to Juice Price and Earnings

Proposed 2014 Medicare Rates Slam Humana and Other Insurers

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

Health and Healthcare Articles

All Health and Healthcare Articles

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

ETF Folly: Biotech ETFs, Nothing but Confusion

VIVUS Obesity Drug Sales Only About 60% of Expectations

FDA Response Letter Takes over $100M from Dynavax Value

Deadly Dialysis Injection Recall Implodes Affymax

Celsion Raises Much Needed Capital

Biotech and Bioheath Stocks Raising Capital, Secondary Offerings

Europe Denies Obesity Drug Approval

Repros Blasts Off After FDA Study Clearance

Ambit Biosciences Files for IPO

Chelsea Therapeutics Back on the Map in a Serious Way

Celgene: When Biotechs Use Stock Buybacks to Juice Price and Earnings

Proposed 2014 Medicare Rates Slam Humana and Other Insurers

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

Featured Reads

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up